Ptosis, hereditary congenital, 1

disease

On this page

Summary

Ptosis, hereditary congenital, 1 (MONDO:0979905) is a disease with 1 cohort gene.

At a glance

Cohort genes: 1
ClinVar variants: 9

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	ptosis, hereditary congenital, 1
Mondo ID	MONDO:0979905
OMIM	178300
DOID	DOID:0061149
Is cancer (heuristic)	no

Data availability: 9 ClinVar variants.

Disease family

Classification path: disease › human disease › disease by body system or component › disorder of orbital region › eye disorder › ptosis › congenital ptosis › ptosis, hereditary congenital, 1

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

ClinVar germline variants

9 retrieved; paginated sample, class counts are floors:

5 uncertain significance, 3 benign, 1 benign/likely benign

ClinVar	Variant (HGVS)	Gene	Classification	Review
2396140	NM_024721.5(ZFHX4):c.2488G>C (p.Gly830Arg)	ZFHX4	Uncertain significance	criteria provided, multiple submitters, no conflicts
2431436	NM_024721.5(ZFHX4):c.2144G>A (p.Ser715Asn)	ZFHX4	Uncertain significance	criteria provided, multiple submitters, no conflicts
2438647	NM_024721.5(ZFHX4):c.9364C>T (p.Pro3122Ser)	ZFHX4	Uncertain significance	criteria provided, single submitter
2664833	NM_024721.5(ZFHX4):c.9048C>A (p.Tyr3016Ter)	ZFHX4	Uncertain significance	criteria provided, single submitter
4076341	NM_024721.5(ZFHX4):c.5710dup (p.Ala1904fs)	ZFHX4	Uncertain significance	criteria provided, single submitter
1292647	NM_024721.5(ZFHX4):c.3213T>C (p.His1071=)	ZFHX4	Benign	criteria provided, multiple submitters, no conflicts
1684256	NM_024721.5(ZFHX4):c.3387G>A (p.Ser1129=)	ZFHX4	Benign	criteria provided, multiple submitters, no conflicts
2672270	NM_024721.5(ZFHX4):c.1277G>A (p.Ser426Asn)	ZFHX4	Benign	criteria provided, single submitter
769743	NM_024721.5(ZFHX4):c.5327A>G (p.Glu1776Gly)	ZFHX4	Benign/Likely benign	criteria provided, multiple submitters, no conflicts

Genes & proteins

Mendelian disease overlap and somatic drivers

GenCC: 0 · Orphanet: 1 · OMIM-shared: 0 · Dual-evidence (GWAS+Mendelian): 0

Orphanet rare-disease linkage (cohort genes)

Gene	Orphanet ID	Rare disease
ZFHX4	Orphanet:91411	Congenital ptosis

Cohort genes → proteins

1 cohort genes, 1 distinct canonical proteins.

Evidence partition

Subset	Genes
multi_evidence	1

Cohort genes (full)

Symbol	HGNC	Ensembl	UniProt	Name	Evidence
ZFHX4	HGNC:30939	ENSG00000091656	Q86UP3	Zinc finger homeobox protein 4	clinvar

Cohort function summary

Lead sentence per gene, UniProt-curated.

Symbol	Protein name	Function (lead sentence)
ZFHX4	Zinc finger homeobox protein 4	May play a role in neural and muscle differentiation.

Protein-family classification

Druggable: 0 · Difficult: 1 · Unknown: 0 · Druggable fraction: 0.0

Family distribution

Cohort families vs a genome-wide background (hypergeometric, BH-FDR; fold = observed/expected). Counts kept; sorted by enrichment, so the catch-all Other/Unknown bucket no longer leads.

Family	Genes	Fold	FDR
Transcription factor	1	8.3×	0.121

Per-gene assignment

Symbol	Family	Druggable?	EC	InterPro (top 3)
ZFHX4	Transcription factor	no		HD, Matrin/U1-like-C_Znf_C2H2, Homeodomain-like_sf

Expression context

Cohort genes with no expression data: 0.

1 cohort gene are a single-cell marker in ≥1 SCXA experiment.

Breadth distribution (Bgee present_calls)

Bucket	Genes
narrow (1-5 tissues)	0
moderate (6-20)	0
broad (>20)	1
unknown	0

Top tissues across cohort

Tissue	Cohort genes
adrenal tissue	1
calcaneal tendon	1
tendon	1

Per-gene tissue summary (top 30)

Symbol	Bgee breadth	FANTOM5 breadth	SCXA	Top tissues
ZFHX4	230	ubiquitous	marker	calcaneal tendon, tendon, adrenal tissue

Protein interactions among cohort

Intra-cohort edges: 0.

Hub genes (top 10 by interactor count)

Symbol	Interactor count
ZFHX4	1,255

Structural data

PDB: 0 · AlphaFold-only: 1 · No structure: 0

AlphaFold-only cohort genes (top 30 by pLDDT)

Symbol	UniProt	pLDDT
ZFHX4	Q86UP3

Function

Pathway analysis

Distinct Reactome pathways touched by cohort: 0. Enrichment computed across 1 evidence-associated genes (0 with Reactome annotation).

GO biological processes by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 1 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

GO term	Cohort genes	Fold	FDR	Sample cohort genes
regulation of transcription by RNA polymerase II	1	11.7×	0.086	ZFHX4

Therapeutics

Drug target analysis

Approved (phase 4): 0 · Phase ≥3: 0 · Phased (≥1): 0 · Undrugged: 1

Druggability breadth: 0 of 1 evidence-associated genes (0%) have a ChEMBL target (buckets above are over the deeply-mined display cohort).

Top cohort targets by molecule count

Symbol	Molecules	Max phase
ZFHX4	0	0

Bioactivity and enzyme data

Enzyme cohort genes (≥1 EC): 0.

Pharmacogenomics

Cohort genes with a PharmGKB record: 1; with CPIC/DPWG dosing guidelines: 0.

No cohort gene has a CPIC/DPWG genotype-guided dosing guideline (PharmGKB).

Chemical tractability of cohort targets

0 approved/phased compounds have measured bioactivity against a cohort gene (and aren’t yet in disease-level trials). This is a research / tractability signal, NOT a therapeutic recommendation — a bioactivity row often reflects off-target or screening binding (e.g. promiscuous kinase inhibitors against a cohort kinase), implying no disease mechanism.

Druggability pyramid

Cohort genes binned by druggability tier (high → low):

Tier	Definition	Genes	Symbols
A	Approved (phase 4 drug)	0
B	Phased (≥1) drug, not yet approved	0
C	Druggable family + PDB, no drug	0
D	Druggable family + AlphaFold only, no drug	0
E	Difficult family or no structure, no drug	1	ZFHX4

Undrugged target profiles

1 cohort genes are undrugged. Ranked by ‘starting-point quality’ (assay depth + drugged-partner adjacency).

Symbol	ChEMBL assays	Drugged partners (top 3)
ZFHX4	0	—

Clinical trials & evidence

Clinical trials

Clinical trials: 0.

Cohort genes: ZFHX4